ARTICLE | Clinical News

Afinitor everolimus: Additional Phase III data

October 18, 2010 7:00 AM UTC

Additional data from the double-blind, international Phase III RADIANT-2 trial in 429 patients with advanced carcinoid tumors showed that 10 mg once-daily oral Afinitor plus Sandostatin LAR octreotide led to a median PFS of 16.4 months vs. 11.3 months for placebo plus Sandostatin LAR (p=0.026, HR=0.77, 95% CI: 0.59, 1). An additional statistical analysis of the trial, which adjusted for imbalances in baseline characteristics between the 2 treatment arms and for inconsistencies between the review of radiology scans for disease progression, showed that Afinitor plus Sandostatin LAR significantly reduced the risk of disease progression by 40% vs. placebo plus Sandostatin LAR (p=0.0014). Data were presented at the European Society for Medical Oncology meeting in Milan. ...